Officials said there were “emerging concerns” over the use of the drug.
London (Reuters):
The UK drug regulator on Tuesday directed scientists to suspend the recruitment of participants to try the use of the malaria drug hydroxychloroquine for the treatment or prevention of COVID-19.
The Medicines and Healthcare Products Regulatory Agency (MHRA) said it is following “emerging concerns” about drug use, and also cited a UK trial, in which hospitalized patients with COVID-19 No significant mortality was found in.
(Except for the headline, this story has not been edited by NDTV staff and published from a syndicated feed.)
Recent Comments